Visitors Now:
Total Visits:
Total Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Pharmas Regeneron and Teva shares hit by FDA order

Monday, October 17, 2016 13:31
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) and Teva Pharmaceuticals (NYSE:TEVA) were hit Monday by news of a clinical trial setback for a new pain drug they are co-developing.

US regulators put on hold a clinical trial involving an experimental treatment for chronic low back pain due to safety concerns. Regeneron shares closed down 1.3% at $366.73.

Teva, which is collaborating on the drug, saw its US-listed shares drop during the session although the managed to repair the damage and ended flat at $41.80.

The US Food and Drug Administration had ordered the hold and told Regeneron and Teva to amend the study protocol after observing a case of adjudicated arthropathy – a type of joint disease – in one patient who had osteoarthritis. As a result, Regeneron said it had stopped dosing study patients and was working to design a new study phase that excludes patients with osteoarthritis.

The drug, fasinumab, aims to offer treatment for millions of Americans who suffer from chronic low back pain and osteoarthritis without the use of highly addictive opioids, by targeting proteins that grow nerve cells. Rivals Eli Lilly (NYSE:LLY) and Pfizer (NYSE:PFE) are racing to develop a similar drug, tanezumab, which aims to treat osteoarthritis, back pain and cancer pain, which they aim to submit for approval by 2018.

Story by ProactiveInvestors

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.